Skip to content
Disclosery

BIOS Capital Management, LP

Follow

13F filer, CIK 1813845, Fort Worth, TX

BIOS Capital Management, LP reported $82,622,742 across 6 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-13.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001813845-26-000002

Period
2025-12-31
Reported value
$82.6M
Holdings
6
Top 10 weight
100%
New
1
Sold out
1

Part of the filer group BIOS Capital Management, LP

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
INABnew+253,417$593K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
IN8BIO INCexited-286,664-$622K
LTRNreduced-6,208-$18.8K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0001813845-26-000002, largest first. % of portfolio is the value over $82,622,742, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ACTUACTUATE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 9,893,651 shares; 2025Q1: 9,893,651 shares; 2025Q2: 9,965,079 shares; 2025Q3: 10,049,996 shares; 2025Q4: 10,049,996 shares 10,049,996$61.5M74.44%0Timeline
CGTXCOGNITION THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 6,000,000 shares; 2025Q1: 6,000,000 shares; 2025Q2: 6,000,000 shares; 2025Q3: 6,000,000 shares; 2025Q4: 6,000,000 shares 6,000,000$8.1M9.8%0Timeline
IRDOPUS GENETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 995,249 shares; 2025Q1: 995,249 shares; 2025Q2: 3,683,429 shares; 2025Q3: 3,683,429 shares; 2025Q4: 3,683,429 shares 3,683,429$7.4M8.96%0Timeline
LTRNLANTERN PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,207,709 shares; 2025Q1: 1,207,709 shares; 2025Q2: 1,075,952 shares; 2025Q3: 1,015,715 shares; 2025Q4: 1,009,507 shares 1,009,507$3.06M3.7%-6,208Timeline
RNTXREIN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,690,751 shares; 2025Q1: 1,690,751 shares; 2025Q2: 1,690,751 shares; 2025Q3: 1,690,751 shares; 2025Q4: 1,690,751 shares 1,690,751$1.96M2.37%0Timeline
INABIN8BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 253,417 shares 253,417$593K0.72%newTimeline

Sold out in Q4 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
IN8BIO INCIN8BIO INC286,664$622Kshares

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001813845-26-000002 base2026-02-13acceptance time not in the bulk data set